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Abstract
Purpose There is ongoing controversy on the effectiveness of
psychotherapy in inflammatory bowel disease (IBD). In the
few small studies, cognitive-behavioural therapy (CBT) has
been shown to alleviate symptoms of anxiety or depression.
However, there is little research on the impact of CBT on
physical outcomes in IBD and no studies on long-term effec-
tiveness of CBT.
Methods The present two-arm pragmatic randomised con-
trolled trial aimed to establish the impact of CBT on disease
course after 24 months of observation. The study compared
standard care plus CBT (+CBT) with standard care alone
(SC). CBT was delivered over 10 weeks, face-to-face (F2F)
or online (cCBT). The data were analysed using linear mixed-
effects models.
Results CBT did not significantly influence disease activity as
measured by disease activity indices at 24 months (Crohn’s
Disease Activity Index (CDAI), p = 0.92; Simple Clinical
Colitis Activity Index (SCCAI), p = 0.88) or blood parameters
(C-reactive protein (CRP), p < 0.62; haemoglobin (Hb),
p = 0.77; platelet, p = 0.64; white cell count (WCC),
p = 0.59) nor did CBT significantly affect mental health, cop-
ing or quality of life (all p > 0.05).
Conclusions Therefore, we conclude that CBT does not influ-
ence the course of IBD over 24 months. Given the high rate of
attrition, particularly in the CBT group, future trials should
consider a personalised approach to psychotherapy, perhaps
combining online and one-to-one therapist time.
Keywords Cognitive-behavioural therapy . Disease course .
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Introduction
Inflammatory bowel disease (IBD), of which ulcerative colitis
(UC), Crohn’s disease (CD) and indeterminate colitis are sub-
types, is a chronic relapsing illness of the gastrointestinal tract,
affecting 2.2 million people in Europe [1], 1.4 million people
in the USA [2], 233,000 in Canada [3] and over 75,000 in
Australia [4]. Its course and prognosis are uncertain, and the
current standard treatments available for maintaining remis-
sion are not tolerated by all patients, are not 100 % protective
against relapse even in those who are compliant [5] and place
patients at risk of substantial side effects [6]. The search for a
cure is ongoing.
While a psychological contribution to IBD’s aetiology is at
present uncertain, the illness is associated with significant
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psychological sequelae. Population-based studies have docu-
mented a higher life-time prevalence of depression in IBD
compared with the community, with estimated rates of 27
versus 12 % [7]. A recent prospective cohort study
(n = 2007), using data from the participants included in the
Swiss IBD cohort from 2006 till 2015, demonstrated a highly
statistically significant association between symptoms of de-
pression and clinical recurrence over time (all IBD, p < 0.001;
CD, p < 0.001; UC, p = 0.005) [8]. Other studies link co-
morbid mental symptoms to higher hospitalisation rates [9]
and lower adherence to treatment [10]. Despite these
biopsychosocial interrelations, very few IBD patients with
mental disorders or mental symptoms receive psychothera-
py—less than 40 % according to a recent Dutch study [11].
Part of the reason for low usage of psychotherapy in this
population is poor access to psychologists. For example, a
recent national audit in the UK showed that only 12 % of
IBD services have access to clinical psychology via a defined
referral pathway [12]. However, another significant contribu-
tion is a paucity of evidence that psychotherapies are effective
for symptoms of mental disorders and any somatic complaints
in this population. There have been five systematic reviews of
psychological treatment for patients with IBD since 2006,
collectively evaluating studies of adults and adolescents
[13–17]. Despite this number of reviews, only a handful of
studies are available for each of the psychological treatment
approaches, with the maximum number of studies evaluated
in one review being 21 (n = 1745) [13].
von Wietersheim and Kessler [16] reviewed 14 studies
and concluded that psychological interventions reduced
psychological distress, but there was no clear benefit for
disease course. They identified two studies with longitu-
dinal follow-up of at least 24 months. A German study
examined psychodynamic therapy over 24 months and
concluded it had no effect on disease activity, mental
health or quality of life [18]. An American controlled
retrospective study conducted in 1964 examined psycho-
analytical therapy, with an 8-year observation period, and
concluded that this therapy resulted in a better disease
course than the control condition [19]. In this study, how-
ever, most patients in the treatment group (but not the
control group) had co-morbid major psychiatric disorders.
Goodhand et al. [17] evaluated 17 studies and conclud-
ed that cognitive-behavioural therapy (CBT) was effective
for mood disorders and improved quality of life, while the
psychodynamic and psychoeducation approaches were
found to have little effect on psychological outcomes.
They concurred with von Wietersheim and Kessler [16]
in that they found psychotherapies (of any type) to have
no impact on clinical symptoms of IBD. However, they
noted that most studies included patients in remission or a
mixed sample of active/inactive IBD, making it more dif-
ficult to detect a positive effect. They identified the same
studies with a longitudinal follow-up as von Wietersheim
and Kessler.
A Cochrane review [13] assessed 21 controlled studies, 19
of which were included in a meta-analysis to evaluate psycho-
logical intervention outcomes. They concluded that psycho-
logical interventions (pooled together) had no effect on dis-
tress, disease activity or quality of life in the unselected IBD
patients, with the exception of psychological interventions in
adolescents, which improved mood. The review recommend-
ed further studies into psychotherapies for subgroups identi-
fied as being in need of psychological support and into types
of therapy that may be most useful. While the review was
carefully done using well-established guidelines, fundamental
issues in the approach to what constitutes a psychotherapeutic
intervention make its conclusions problematic. The pooling of
therapy types, each associated with differing efficacy for psy-
chological outcomes in other clinical settings and some show-
ing no effect, may have diluted any positive effect in the meta-
analysis. In fact, the conclusion that psychological therapy
was beneficial for adolescents only may have had less to do
with the type of participants andmore to dowith including just
CBT interventions. CBT is very well established as evidence-
based treatment for depression [20]. Moreover, half the in-
cluded studies were psychoeducational interventions, which
are not really psychotherapies, and have at best questionable
efficacy in the general population. As such, it does not seem
appropriate to conclude that psychological treatment is inef-
fective in IBD, based on those studies. The Cochrane review
identified three studies with the longitudinal follow-up of at
least 24 months. A German study already identified in previ-
ous reviews showed no effect of psychodynamic therapy on
any of the outcomes [18]. A small study fromBrazil examined
social support (unclear of what psychological paradigm) for a
period of up to 24 months and demonstrated no impact of the
intervention on quality of life (no group difference identified)
[21]. Another small trial on hypnotherapy plus peer group
sessions followed participants for 5 years and reported a pos-
itive effect of the intervention on wellbeing (not defined);
however, results were not reported in detail [22].
Two recent systematic reviews addressed shortcomings of
the prior reviews [14, 15]. McCombie et al. [15] reassessed all
the Cochrane review papers, ultimately evaluating 18 con-
trolled studies of psychological treatment, including eight
used in the Cochrane review, three that the Cochrane review
had excluded and seven published since. They deliberately
excluded psychoeducational studies. However, similarly to
Timmer et al. [13], they synthesised findings across the vari-
ous types of psychological treatment. For almost every out-
come, they concluded the findings were mixed, with the ex-
ception of agreement of positive outcomes for pain and fa-
tigue. CBT and its variants most commonly contributed to
positive outcomes as compared with other psychotherapies,
while counselling and psychodynamic therapy more typically
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yielded negative results. They identified just one study which
used a longitudinal follow-up of 2 years (already reported by
previous reviews) [18].
Like McCombie et al. [15], Knowles et al. [14] excluded
psychoeducational studies and included both controlled and
uncontrolled studies of the main types of psychological treat-
ment used for adults with IBD (i.e. stress management, CBT,
psychodynamic therapy, hypnotherapy). CBT interventions
(n = 5) consistently resulted in improved psychological dis-
tress, with modest but unsustained changes in gastrointestinal
symptoms. Stress management studies (n = 5) had mixed out-
comes, with one reporting improved anxiety and two
reporting reduction in clinical disease indices post-treatment.
Two of the four psychodynamic studies found reductions in
psychological distress, and one reported decreased healthcare
utilisation. There was only limited evidence of improved qual-
ity of life for any of the treatments. Knowles et al. have iden-
tified three studies with longitudinal follow-up, two already
reported by previous reviews [18, 19] and one not previously
reported [23]. The small and uncontrolled study byMiller and
Whorwell [23] tested gut-focused hypnotherapy following
their participants for a mean duration of 5.4 years and con-
cluded that hypnotherapy improved disease activity and qual-
ity of life.
Interestingly, the majority of the studies included in the
above reviews did not look at clinical levels of anxiety/
depression and relied on screening measures rather than an
interview, which is a gold standard of psychological/
psychiatric diagnosis. Thus, it needs to be acknowledged that
until studies start being conducted with populations with sig-
nificant levels of psychopathology rather than low level emo-
tional distress, we may not be certain whether psychotherapy
(of any type) helps IBD patients for their associated anxiety,
depression and distress.
To summarise the current evidence for the usefulness of
psychotherapy in IBD, there is some support for positive ef-
fect of psychological treatments (particularly CBT), on anxi-
ety or depression, but no consistent evidence of improved
bowel symptoms. Five studies have examined long-term ef-
fectiveness of psychotherapy in IBD, with mixed results [18,
19, 21–23], none of which tested CBT.
The present study was designed to address the gaps in
knowledge on the long-term role of psychotherapy, and
CBT in particular, on disease activity in IBD. Our hypothesis
was that since stress is one of the strongest predictors of dis-
ease activity [24], learning CBTskills may ‘inoculate’ patients
against stresses of everyday life (of any type but specifically
related to IBD itself), which, in turn, may lead to less-frequent
IBD flares. We have also specifically addressed the manage-
ment of IBD-related concerns. We thus conducted a
randomised controlled trial to investigate whether adding
CBT to standard treatment prolongs remission in IBD in com-
parison with standard therapy alone. Our first analysis
(reported elsewhere [25]) covered the period of 12 months
and showed no difference in remission rates between groups,
with similar numbers flaring at 12 months. Similar results
were found for the secondary outcome measures of quality
of life and mental health. However, in a sub-analysis, we ex-
amined the effect of the intervention in participants classified
as in need of psychological support (young, high baseline IBD
activity, recently diagnosed; poor mental health; n = 74, 34
CBT and 40 controls) and showed that CBT significantly im-
proved the secondary outcome of mental quality of life
(p = .034, d = .56) at 6 months. The present paper reports on
24-month outcome data for the described intervention, with
the aim to establish whether CBT has any effect on IBD re-
mission status after 24 months of observation.
Methods
Design
We conducted a randomised controlled trial and the detailed
methods as well as the data for the first 12 months of obser-
vation have been reported elsewhere [25]. Briefly, the study
was a two-arm parallel pragmatic randomised controlled trial
(RCT), comparing standard care plus CBT (+CBT) with stan-
dard care alone (SC). The trial’s design was pragmatic as those
in the experimental group were offered a choice of completing
the intervention face-to-face (F2F) or online (cCBT).
Intervention
F2F CBT group met weekly at a tertiary hospital for
10 weeks for 2-h sessions delivered by a qualified clinical
psychologist while cCBT group received sessions with the
same content online (self-directed). The psychologist’s
training and supervision were provided by the Clinical
Psychology Department at the Royal Adelaide Hospital.
Treatment adherance was maintained by using the same
protocol for both groups within the CBT arm. The pro-
gramme focused on improving coping with IBD. Sessions
are presented in Table 1. They can be accessed elsewhere
(http://www.tameyourgut.com/). More detail on the
programme is available in our original paper [25]. The
study was registered in the Australian New Zealand
Trial Registry (ACTRN12609000913279).
Participants and Sample Size
Participants were recruited from two gastroenterology
clinics in Australia and had a clinically established diag-
nosis of IBD, were in clinical remission or had mild
symptoms only for at least 3 months, were aged 18 years
or over and had competence to consent. Those with
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serious mental illness (e.g. psychosis, schizophrenia or
any other serious mental disorder requiring one-to-one
therapy which could not be offered as part of the trial)
or receiving psychotherapy elsewhere were excluded. The
power calculation was based on the primary outcome
measure, remission at 12-month follow-up for the two
main groups (cCBT and SC). With 80 patients per arm,
the study had 80 % power at the 0.05 level to detect a
20 % difference in the proportion of patients remaining in
remission between the +CBT group (0.80) and SC (0.60)
arms.
In the original paper [25], we identified a group of
patients in need of additional support who appeared to
benefit from the CBT intervention at 6 months, with im-
proved mental quality of life (p = .034, d = .56). This
group was created based on the recommendations from
other studies regarding who may benefit from psychother-
apy in IBD [13, 26], validated by our own clinical judge-
ment of at risk groups. Participants in need of support
were defined as either being recently transitioned from
paediatric care (aged 18–20 years), having high baseline
IBD activity despite being in IBD remission (the Crohn’s
Disease Activity Index (CDAI) >180; the Simple Clinical
Colitis Activity Index (SCCAI) >5 while the clinician
considered them to be in remission), being diagnosed
within last 2 years, having poor coping (a score of 20–25 on
either the adaptive or maladaptive coping subscale of Brief
COPE) or high anxiety or depression (the Hospital Anxiety
and Depression Scale (HADS) score for either anxiety or de-
pression subscale ≥15) [25]. Here, we have included this
group in a sub-group analysis.
Measures
The primary outcome measure for the present longitudinal
study was IBD remission at 24 months (established using
the CDAI [27] for those with CD or the SCCAI [28] for those
with UC). The secondary measures were patient subjective
view of IBD activity measured by a question How well con-
trolled is your IBD?; disease activity measured on the blood
parameters: C-reactive protein (CRP), haemoglobin (Hb),
platelet, white cell count (WCC), quality of life as measured
on the Short Form 36 Health Status Questionnaire (SF-36)
[29, 30] and mental health status (anxiety and depression as
measured on the HADS [31] and the State-Trait Anxiety
Inventory (STAI) [32], stress measured on the Revised
Social Readjustment Rating Scale (RSRRS) [33] and coping
as measured on the Brief COPE [34] and the IBD Stages of
Change Coping Questionnaire (IBDSCCQ) developed by the
Table 1 CBT programme’s
content Week
number
Theme Activities
1 Education about IBD and
introduction to the programme
Video materials about IBD in general and diet in IBD; goal
setting
2 Stress and relaxation What is stress—its physiology, fight or flight response,
symptoms of stress, observe yourself in stressful situations;
relaxation training—4 voice recorded sessions of
relaxation exercises
3 Automatic thoughts and cognitive
distortions
Thinking, feeling and behaviour—introducing CBT basic
concepts, observe your thoughts and feelings, identify core
beliefs; another 2 recordings to practice relaxation
4 Cognitive restructuring Emotional wellbeing, appraisal of mood, automatic
thought—identify and challenge them
5 Exposure and overcoming
avoidance
Avoidance and conditioning—how do we learn to be afraid
and how do we overcome conditioning; desensitisation;
another 2 recordings of relaxation skill building
6 Coping strategies What is coping, how do we cope with stress and IBD; worry
and sleep; relaxation to help you sleep
7 Assertiveness training Taking responsibility; introducing assertiveness in
communication with family and health professionals;
learning to say no
8 Relationships and communication Social support—quality and quantity; maintaining social
networks and interests when dealing with IBD;
communication strategies
9 Attention and distraction Techniques to manage IBD-related pain and discomfort—
imagery, focus, distraction
10 Maintaining good mental health Keeping up momentum—how not to forget what you have
learnt; review old goals and plan new ones
130 Int.J. Behav. Med. (2017) 24:127–135
investigators based on the work by Carr [35] and the Trans-
Theoretical Model of behavioural change [36] at 24 months.
Analysis
The study applied the intention-to-treat principle. The
multivariate analyses were conducted using linear
mixed-effects models which allowed for the retention of
all subjects in the model including those with missing
data. A p value of less than .05 was considered statisti-
cally significant. Data were analysed using the Stata 14
statistical package.
Results
The CONSORT diagram (Fig. 1) presents the flow of
participants between the study commencement and 24-
month data collection. Of the 174 participants who com-
pleted baseline measures, 75 remained in the study until
the 24-month follow-up (+CBT, n = 30; SC, n = 45). There
was significant attrition observed in both groups, with
+CBT group participants dropping from the trial in great-
er numbers (67 % in +CBT vs. 46 % in SC, p = 0.007).
The majority of the participants who dropped out of the
study were either not contactable (we were allowed by the
Research Ethics Committee to attempt contact up to three
Invitations sent  
 (n = 1811) 
Excluded (n = 7) 
Not meeting inclusion criteria 
   (n = 1, IBD became active) 
  Not contactable 
   (n = 6) Randomized (n = 176)
Allocated to intervention 
(n = 92) 
Withdrew before intervention 
commenced due to time constrains 
(n = 2)
Received allocated intervention (n 
= 67) 
Did not access online CBT (n = 
23) 
A
llo
ca
tio
n 
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t 
Control group 
(n = 84) 
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s 
Analysed at 24 months 
(n = 30) 
Analysed at 24 months 
(n = 45) 
Agreed to participate 
 (n = 183) 
Lost to follow up 24 months 
(n = 39)  
Not contactable / no reason n = 36 
Deceased n = 2 
Dementia n = 1 
Lost to follow up 24 months 
(n = 60)  
Not contactable / no reason n = 50 
Too busy n =7 
Pregnant n = 1 
Deceased n = 1 
Cataracts n = 1
Fig. 1 CONSORT diagram
showing the flow of participants
through the study
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times) or did not provide the reason for study withdrawal.
Of the 174 participants, 68 opted to use cCBT and 22
were allocated to F2F CBT.
Outcome Measures
Table 2 describes self-reported disease activity at baseline
and 24 months. Table 3 reports blood parameters at base-
line and 24 months. Table 4 reports self-reported psycho-
logical variables at baseline and 24 months, including
quality of life, depression, anxiety, coping, stress and
stages of change.
At the multivariate level (adjusting for baseline), CBT
did not significantly change disease activity as measured
on the CDAI and the SCCAI at 24 months (CD, p = .92;
UC, p = .87) or blood parameters (CRP, p = .61; Hb,
p = .77; platelet, p = .64; WCC, p = .59) nor did CBT sig-
nificantly affect mental health, coping or quality of life
(all p > .05). Controlling for sex and age did not alter
the results. There was a trend towards reduced state
(p = .29) and trait (p = .24) anxiety in +CBT group; how-
ever, it was not statistically significant.
At 24 months, of the original group comprising 74 in need
of support participants, only 24 remained in the study (6 +
CBT and 18 SC). CBT did not significantly change the score
on any variable of interest in the participants in need of sup-
port (all p > .05); however, the experimental and the control
groups were numerically imbalanced and the comparisons
underpowered.
Discussion
This longitudinal follow-up to a 10-week CBT intervention
for IBD shows no long-term effect of CBT on disease param-
eters or mental health in the unselected IBD participants.
While previous CBT trials have shown positive short-term
effect of CBT on mental health in IBD [14], no previous
CBT trial has provided follow-up data up to 24 months.
In the present study, the main outcome of interest was dis-
ease course. We aimed to test whether gaining CBTskills may
‘inoculate’ patients against stresses of everyday life, which, in
turn, may lead to less frequent IBD flares. Psychological
stress, reported by large numbers of IBD patients, has been
found to be a significant predictor of disease course in IBD in
the recent large-scale population-based study [24]. In the pres-
ent trial, we did not find confirmation of the CBT’s preventive
role in reducing IBD’s activity, a finding consistent with the
unsustained changes in gastrointestinal symptoms reported by
the few previous CBT trials [14]. However, one of the prob-
lems in ascertaining the long-term effect of CBT on IBD ac-
tivity (other than high attrition) is the fact that very few study
participants flared during the time of observation, with the
large majority of patients reporting no or minimal IBD activity
during the 24 months. The exception appears to be some par-
ticipants with UC. However, we previously documented the
problems with the accuracy of the SCCAI in reporting disease
activity [25] and given very low numbers of patients reporting
poor IBD control on the patient subjective measure, as well as
consistent blood test results over time, this worsening of
symptoms in UC seems to result from the inaccuracy of the
measure rather than being a true reflection of disease activity.
A calprotectin test of faecal inflammation could have poten-
tially been used in the present study to ensure that inflamma-
tion (and thus disease activity) is reliably detected.
Unfortunately at the point of this study’s commencement
calprotectin had not been available at the participating sites.
In any case, a 24-month follow-up does not appear a sufficient
period to capture the course of IBD. Longer time frames of 5
to 10 years may offer more information on the impact of
medical and psychological interventions on IBD activity. In
addition, future studies could also focus on people with active
Table 2 Disease activity at baseline and 24 months
+CBT SC
Baseline n = 90 24 months n = 31 Baseline n = 84 24 months n = 45
n (%) Mean (SD) n (%) Mean (SD) n (%) Mean (SD) n (%) Mean (SD)
IBD control
Very good 27 (30) 11 (36.7) 18 (21.4) 11 (26.2)
Reasonable 54 (60) 17 (56.7) 56 (66.7) 29 (69)
Poor 7 (8) 2 (6.7) 6 (7.1) 2 (4.8)
CDAI (active >150) 15 (17) 2 (6.4) 11 (13.1) 3 (6.6)
SCCAI (active >3) 8 (9) 6 (19.3) 10 (11.9) 15 (33.3)
CDAI 110.8 (72.5) 60.4 (91.2) 87.4 (104.8) 53.1 (70.6)
SCCAI 3.4 (1.4) 4.7 (1.7) 3.2 (1.3) 4.9 (2.1)
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disease. In the present study, we included only those partici-
pants with remitted or mild disease and we have thus likely
excluded those individuals in whom emotional distress and
disease are most interactive. While examining the long-term
disease course in people in remission made sense in testing
our hypothesis of whether CBT extends the period of remis-
sion, it would be of interest to examine whether psychothera-
py performs better in people who are flaring with their IBD
than in those in remission.
Retention of participants in the study and ensuring that
those assigned to the intervention actually comply with the
study requirements (i.e. complete a significant number of ses-
sions) is another obstacle to conducting psychotherapy inter-
ventions which rely on online resources. As detailed in our
previous paper [25], in the present trial, 25 % of those
assigned to the CBT group did not complete a single CBT
activity, despite the reminders by the study manager. In the
recent CBT trial for IBD which tested a modified version of
the present intervention in New Zealand [37], while nearly
90 % of participants in the experimental group accessed the
CBT programme, only 26 % downloaded at least half of the
resources on offer. This, as well as higher dropout rates in the
experimental group versus controls, is in line with other online
CBT trials for mental disorders, as evidenced by a recent sys-
tematic review [38]. The latter paper points to a significant
staff time needed to support depressed clients through online
CBT to reduce attrition. Exclusively, online CBTmay thus not
be an ideal solution for the IBD population, and adding some
therapist-run sessions in order to offer a more personalised
approach may reduce attrition. Providing standard face-to-
face therapy may prove to be the safest option to achieve
meaningful therapeutic outcomes in IBD until good quality
trials propose new approaches to online psychotherapy deliv-
ery. While tailoring therapy to individual needs is more re-
source intensive up front, it might yield better outcomes over
time than the relatively cheap self-directed online
Table 3 Blood results at baseline
and 24 months +CBT (mean (SD)) SC (mean (SD))
Baseline n = 69 24 months n = 31 Baseline n = 70 24 months n = 45
CRP 3.6 (5.4) 6.2 (10.2) 6.2 (8.3) 4.4 (10.8)
HB 136.6 (21.8) 140.9 (17.1) 141.9 (15.4) 136.4 (14.7)
Platelet 260.9 (72.8) 258.9 (63.4) 266.4 (63.2) 269.8 (77.1)
WCC 5.9 (1.8) 6.6 (2.4) 6.6 (2.1) 6.4 (1.7)
Table 4 Mental health and
quality of life at baseline and
24 months
+CBT (mean (SD)) SC (mean (SD))
Baseline
n = 90
24 months
n = 31
Baseline
n = 84
24 months
n = 45
Physical QoL 46.7 (9.3) 48.8 (10.9) 47 (10.3) 48.8 (8.5)
Mental QoL 44.8 (11.4) 49.8 (8.8) 48.1 (11.5) 48.8 (10.9)
HADS anxiety 7.1 (3.9) 5.3 (4.1) 6.2 (4.3) 5.5 (4.7)
HADS depression 4.3 (3.4) 3.2 (3.7) 4.4 (4.1) 3.9 (3.7)
State anxiety 37.5 (13.1) 32.2 (11.3) 35.9 (13.7) 37.7 (14.7)
Trait anxiety 39.3 (11.9) 33.6 (10.4) 37.4 (11.7) 38 (14.1)
Adaptive coping (range, 20–80
(higher is better))
42.7 (12.8) 43.5 (17.5) 39.5 (11.3) 41.1 (24.1)
Maladaptive coping (range, 8–32 (the
lower the better))
10.9 (3.6) 11.6 (10.3) 10.7 (3.7) 12.2 (9.9)
Stress (>300 high stress 150–299
moderate stress <150 low stress)
638.3 (665.9) 338.7 (308.1) 453.6 (490.5) 442.9 (551.1)
TTM stage (range, 2–10
(higher scores
mean greater agreement))
Pre-contemplation 4.5 (1.6) 4.6 (2.2) 4.4 (1.6) 4.9 (2.9)
Contemplation 6.7 (2.1) 6.5 (2.1) 6.3 (2.1) 6.1 (2.7)
Preparation 6.3 (2.3) 6.8 (2.1) 5.7 (2.3) 6.7 (3.1)
Action 5.8 (2.2) 6.4 (2.1) 5.5 (2.1) 6.3 (3.3)
Maintenance 7.1 (1.9) 7.5 (1.6) 7.2 (1.3) 7.6 (2.4)
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psychotherapies. A recent high-quality systematic review and
a meta-analysis on depression (not in the gastroenterology
context) showed that guided self-help interventions result in
effects comparable with face-to-face therapies [39], while un-
guided self-help produces small, but significant effects [40].
Of closer relevance, a recent systematic review conducted on
psychotherapies for irritable bowel syndrome showed that ‘no
therapist’ interventions produce little effect while ‘minimal
contact’ therapies have the potential to reduce healthcare seek-
ing behaviour and potentially reduce healthcare costs [41].
Interestingly, IBD patients surveyed in a recent New
Zealand study (n = 102) report preference towards online ther-
apies as compared with face-to-face psychotherapies [42] and
thus a search towards an effective online psychotherapy
should not cease, yet should clearly involve therapists in the
delivery. In addition, in future trials, high attrition rates should
be factored into sample size calculations.
Finally, the present trial leans towards the recommenda-
tions of the Cochrane review [13] in that psychotherapy does
not appear to benefit all IBD patients, and subgroups in need
of such an intervention may in fact benefit more than unse-
lected IBD patients. While in our previous paper we showed
benefits for the sub-group of participants with identified prob-
lems (i.e. the so-called in need of support participants) [25] at
6 months, these trends were not maintained at 24 months.
Given a small sample and the fact that the present study had
not been powered to show effect in this sub-population, future
trials should examine the effectiveness of psychotherapy for
groups in need of support over an extended period.
Limitations
There are relevant psychotherapy factors that were not
assessed in this trial such as participant expectancy and for
face-to-face modality—connection with therapist, which
should be measured in future trials. CBT-specific factors such
as, for example, cognitive shifts or reduction in avoidance
were not measured and could possibly shed light on why the
programme was not effective. Heterogeneity of inclusion
criteria, high attrition and low treatment dosage are other lim-
itations relevant to the trial’s findings’ generalisability.
Conclusions
CBT does not appear to influence disease course in IBD at
24 months in the unselected IBD participants, as measured by
disease activity indices and blood parameters, nor does it sig-
nificantly affect mental health, coping or quality of life.
However, a 24-month period of observation was shown not
to be adequate to allow for observing changes in disease ac-
tivity and longer times of observation are recommended for
future studies. Given high attrition, particularly in the CBT
group, future trials should consider a personalised approach
to online psychotherapies, combining online psychotherapy
with one-to-one therapist time. The high attrition should also
be factored in power calculations. Future trials should also
examine the effectiveness of psychotherapy for groups in need
of support as opposed to unselected IBD patients.
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